Dr. John Cush RheumNow
1 year 8 months ago
Off-Label Use of JAK Inhibitors in Orphan Diseases and Other Conditions?
The issues surrounding publication bias are real.
https://t.co/gIFNjAsoM6 https://t.co/UstQGvJX7H
Dr. John Cush RheumNow
1 year 8 months ago
UK study compared 16,634 female RA pts vs 65,448 controls and found all RA women at incr risk for VTE (thrombosis)[aHR=1.52) irrespective of estrogen contraceptives/HRT. Contraceptives did not increase VTE risk (aHR 2.32; 0.92, 5.85, p=0.08) #ACR24 https://t.co/AzBXI0W5dv https://t.co/Q4TaKq2ReC
Dr. John Cush RheumNow
1 year 8 months ago
Osteoarthritis (OA) affects 53.2 million in the USA & is projected to rise significantly by 2040. Societal costs are $132 billion ($11,00 per/pt). OA is the 3rd most rapidly rising disability, behind diabetes and dementia. https://t.co/n3Rwjjsio3 https://t.co/FPDWd6gEpi
Unlike traditional imaging techniques, MSUS can be easily used at the point-of-care and offers high-resolution images of joints, tendons, and soft tissues, facilitating the early detection of inflammation and structural damage. On Saturday, November 16th at the ACR Convergence 2024, Dr. Veena Ranganath, Dr. Gurjit Kaeley, and Dr. Catherine Bakewell will present the “Proposed ACR Guidance for Use of Musculoskeletal Ultrasound in Rheumatoid and
Dr. John Cush RheumNow
1 year 8 months ago
Primary Hypophosphatemia (HYPOPH) - Japan study 50,136 adults w/ 424,434 alk phosphatase (ALP) tests. Persistent HYPOPH seen in 0.54% (273) due to cancer(30%), steroids(21%), DMARDs (16%). Unexplained HYPOPH had pain, muscle weakness, fatigue & could have primary HYPOPH… https://t.co/8RbSnhS3vl https://t.co/NdRIA4oREr
Dr. John Cush RheumNow
1 year 8 months ago
ACR24 JAK/TYK Topic Panel https://t.co/xTDnwjEXE6
Dr. John Cush RheumNow
1 year 8 months ago
J&J has submitted 2 supplemental BLAs applying for FDA approval of guselkumab( Tremfya) for use in juvenile plaque psoriasis & juvenile (>5-6 yrs age) psoriatic arthritis based on several phase 3 RCTs. https://t.co/dAkH219pzN https://t.co/R9yJCSOVJa
Dr. John Cush RheumNow
1 year 8 months ago
Another Stelara (Ustekinumab) biosimilar was FDA approved on 12/1 -- called Yesintek for the treatment of Crohn’s, Ulcerative Colitis, Psoriasis & PsA. This makes 6 FDA approved biosimilars for ustekinumab.https://t.co/ASErsKTNQ6 https://t.co/d1BRW92vju
Dr. John Cush RheumNow
1 year 8 months ago
In a phase II DBRPCT, Cenerimod (sphingosine-1-phosphate recptr modulator) was not shown effective (vs PBO) at 12 mos in active, SLE pts. CARE study enrolled 427 SLE pts who were randomized to Placebo or 3 different doses of CEN - primary endpoint was not met.… https://t.co/AR6NsEsv8S https://t.co/i89ANl5dai
Dr. John Cush RheumNow
1 year 8 months ago
Ozempic will change rheumatology @drdavidliew
Ozempic is everywhere. Even all the way in Australia, where we have highly constrained supply that makes headlines and substantial limits on direct-to-consumer advertising, somehow I know the jingle from the American ad for Ozempic.… https://t.co/lELDs7Yy5W https://t.co/wuXZR4vkx8
